{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"20.59","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"CNS disease progression was defined as a new CNS lesion or progression of pre-existing CNS lesions according to RECIST v1.1. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib 600 mg (Fed): Phase II"}],"paramType":"NUMBER","populationDescription":"Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter (assessed up to 194 weeks) (1 cycle = 21 days)","title":"Percentage of Participants With CNS Progression According to RECIST v1.1 by IRC: Phase II","type":"SECONDARY","unitOfMeasure":"percentage of participants"}